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 COPD causes signiﬁ cant morbidity and mortality, and is the fourth leading cause of death in the 
world. 1 Hypercapnic respiratory failure in COPD 
worsens the prognosis and increases the mortality. 2-5 
Noninvasive positive pressure ventilation (NIPPV) is 
now established as the standard treatment of respira-
tory failure in acute exacerbation of COPD 6 ; however, 
26% to 54% of these patients still require invasive 
positive pressure ventilation (IPPV). 7,8 The prognosis 
for patients with COPD who require IPPV is poor 
with hospital survival ranging from 31% to 76%. 6,9,10 
 As an adjunct to IPPV, extracorporeal CO 2 removal 
(ECCO 2 R) techniques were ﬁ rst applied to patients 
with hypoxic respiratory failure over three decades 
ago 11,12 but have not achieved widespread use. Curi-
ously, the application of ECCO 2 R speciﬁ cally for 
hypercapnic respiratory failure has not been well stud-
ied. We describe here a pilot study of the application 
 Background :  Hypercapnic respiratory failure in patients with COPD frequently requires mechan-
ical ventilatory support. Extracorporeal CO 2 removal (ECCO 2 R) techniques have not been sys-
tematically evaluated in these patients. 
 Methods :  This is a pilot study of a novel ECCO 2 R device that utilizes a single venous catheter with 
high CO 2 removal rates at low blood ﬂ ows. Twenty hypercapnic patients with COPD received 
ECCO 2 R. Group 1 (n  5 7) consisted of patients receiving noninvasive ventilation with a high like-
lihood of requiring invasive ventilation, group 2 (n  5 2) consisted of patients who could not be 
weaned from noninvasive ventilation, and group 3 (n  5 11) consisted of patients on invasive ven-
tilation who had failed attempts to wean. 
 Results:  The device was well tolerated, with complications and rates similar to those seen with cen-
tral venous catheterization. Blood ﬂ ow through the system was 430.5   73.7 mL/min, and ECCO 2 R 
was 82.5   15.6 mL/min and did not change signiﬁ cantly with time. Invasive ventilation was avoided 
in all patients in group 1 and both patients in group 2 were weaned; Pa CO 2 decreased signiﬁ cantly 
( P  , .003) with application of the device from 78.9   16.8 mm Hg to 65.9   11.5 mm Hg. In group 3, 
three patients were weaned, while the level of invasive ventilatory support was reduced in three 
patients. One patient in group 3 died due to a retroperitoneal bleed following catheterization. 
 Conclusions:  This single-catheter, low-ﬂ ow ECCO 2 R system provided clinically useful levels of 
CO 2 removal in these patients with COPD. The system appears to be a potentially valuable addi-
tional modality for the treatment of hypercapnic respiratory failure. 
 Trial registry:  ClinicalTrials.gov; No.: NCT00987740 and 01021605; URL: www.clinicaltrials.gov 
   CHEST 2013; 143(3):678–686 
 Abbreviations:  ECCO 2 R  5 extracorporeal CO 2  removal; IPPV  5 invasive positive pressure ventilation; NIPPV  5 nonin-
vasive positive pressure ventilation; VAS  5 visual analog score 
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were considered eligible for study inclusion. Group 1 (n  5 7) con-
sisted of patients with acute exacerbation of COPD on NIPPV 
therapy with a very high likelihood ( . 50%) of requiring intubation 
and IPPV. 7,14 Patients in this group had been on NIPPV for at least 
1 h with either Pa co 2  . 55 mmHg and pH  , 7.25 or pH  , 7.30 
and Pa co 2  . 55 mm Hg, with  , 5 mmHg Pa co 2 decrease from 
baseline following NIPPV application. Group 2 (n  5 2) consisted 
of patients with hypercapnic respiratory failure requiring NIPPV 
who had failed two weaning attempts and did not wish to be inva-
sively mechanically ventilated. Group 3 (n  5 11) consisted of patients 
with hypercapnic respiratory failure already on invasive mechan-
ical ventilation who had either failed two or more weaning attempts 
or failed one weaning attempt and did not wish to continue inva-
sive mechanical ventilation. 
 For each subject, written informed consent (as approved by 
each site’s institutional review board) was obtained (institutional 
review board committee names and project approval numbers for 
all centers are included as a data supplement in e-Table 1). Con-
secutive patients with COPD presenting with hypercapnic respi-
ratory failure were evaluated, and subjects meeting the inclusion 
criteria were enrolled. The diagnosis of COPD was based on med-
ical history, physical examination, and pulmonary function tests 
indicating airways obstruction. 1 Patients with hemodynamic insta-
bility, sensitivity to heparin, recent major surgery, uncontrolled 
arrhythmia, thrombocytopenia (platelets  , 100,000/mm 3 ), a bleeding 
diathesis, or coma from any cause were excluded from the study. 
 The double-lumen catheter was placed in either the femoral 
(n  5 13) or jugular vein (n  5 7) and advanced to the vena cava. A 
loading dose of heparin (80 units/kg) was administered, and the 
heparin dose was adjusted to maintain the activated partial throm-
boplastin time at 1.5 to 2.3 times baseline as long as the catheter 
was in situ. Blood ﬂ ow through the catheter was initiated at 400 mL 
to 500 mL/min to achieve a CO 2 removal rate  . 50 mL/min. The 
CO 2 removal rate and blood ﬂ ow, displayed on the Hemolung 
controller, were continuously monitored and recorded. Baseline 
blood samples for measurements of hematologic parameters, elec-
trolytes, and liver function tests, as well as arterial blood gas mea-
surements, were made. These measurements were repeated serially 
at intervals throughout the period as long as the ECCO 2 R cath-
eter was in situ. In addition, daily measurements of dyspnea using 
a visual analog scale (VAS) were made when possible. 15 Group 1 
patients on ECCO 2 R and NIPPV were considered for intubation 
if there was a worsening or lack of improvement of the arterial 
blood gases, deﬁ ned as an arterial pH  , 7.25 or an increase in 
Pa co 2  . 10 mmHg after 2 h of treatment, or worsening of respira-
tory distress, deterioration of neurologic status, intolerance of 
face/nasal mask, inability to clear secretions, or life-threatening 
cardiovascular instability. In each case, the ﬁ nal decision was made 
by the attending physician/principal investigator. All patients were 
followed to hospital discharge or 30 days after discontinuance of 
ECCO 2 R. 
 Results 
 Twenty patients with COPD with hypercapnic 
respiratory failure received ECCO 2 R therapy ( Table 1 ) 
for a mean of 104.2   59.7 h (range, 0.2-192 h). The 
individual ventilatory parameters are shown in  Table 2 . 
The device was well tolerated by the patients and inva-
sive ventilation was avoided in association with ECCO 2 R 
therapy in all patients in group 1; in one patient, 
ECCO 2 R was stopped after 20 min due to inadequate 
anticoagulation. Three patients in this group died 
within 30 days after completion of ECCO 2 R therapy 
of a novel, single venous catheter ECCO 2 R system in 
patients with COPD with hypercapnic respiratory fail-
ure conducted in India (single center) and in Germany 
(ﬁ ve centers). 
 Materials and Methods 
 ECCO 2 R Device 
 The ECCO 2 R device (Hemolung Respiratory Assist System; 
ALung Technologies Inc) was applied in three groups of patients 
with COPD with hypercapnic respiratory failure. This ECCO 2 R 
device has been described in detail previously and consists of a 
catheter, an integrated pump/gas-exchange cartridge, and a con-
troller assembly. 13 The size 15.5F dual-lumen catheter is available 
in either a femoral or internal jugular conﬁ guration ( Fig 1 ), and is 
inserted percutaneously and advanced to the inferior or supe-
rior vena cava. Venous blood is withdrawn through the double-
lumen catheter by a centrifugal pump magnetically driven by the 
Hemolung controller unit, where it ﬂ ows past a cylindrical bundle 
of hollow fibers assembled around a rotating core. Sweep gas 
(air or oxygen) is drawn through the hollow ﬁ bers by a vacuum 
pump (to prevent air embolism in the event of ﬁ ber breakage), 
creating a diffusion gradient for gas exchange across the membrane. 
The venous blood is returned to the patient through the double-
lumen catheter. Unlike conventional passive oxygenators, the pump-
driven enhanced ﬂ ow past the membranes markedly increases 
gas-exchange efﬁ ciency, allowing for signiﬁ cant CO 2 removal at 
relatively low blood ﬂ ow in the range of 300 to 500 mL/min. 
The rate of CO 2 removal is calculated and displayed on the con-
troller monitor based on internal measurements of CO 2 percent-
age and ﬂ ow in the hollow-ﬁ ber membrane sweep gas. This device 
has been studied in animals for up to 8 days, and was, therefore, 
limited in the clinical feasibility study to a maximum of 7 days 
(or 168 h) of therapy. 
 Subjects 
 Three groups of patients, aged 21 to 80 years, with COPD and 
hypercapnic respiratory failure (Pa co 2  . 50 mm Hg, pH  , 7.3) 
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 The application of ECCO 2 R resulted in a decrease in 
the sensation of breathlessness. Systematic assessment 
of breathlessness by VAS was available in ﬁ ve sub-
jects in whom there was a signiﬁ cant decrease in breath-
lessness: baseline VAS score, 7.2   2.2 vs 3.56   1.59 
at 48 h (n  5 5,  P  , .027). 
 Blood ﬂ ow through the system ( Fig 2 ) ranged 
between 117 and 587 mL/min (mean   SD of 430.5   
73.7 mL/min). ECCO 2 R ranged from 14 to 121 mL/min 
(mean   SD of 82.0   16.3 mL/min) with the lower 
ﬁ gures representing weaning from the device. Over 
the course of ECCO 2 R therapy, blood flow and 
CO 2 removal did not change signiﬁ cantly in these 
patients. 
 In patients from groups 1 and 2 on NIPPV, there 
was a signiﬁ cant decrease ( P  , .003, paired  t test) in 
Pa co 2 within 1 h of the application of the device from 
78.9   16.8 mm Hg to 65.9   11.5 mm Hg, and a sig-
niﬁ cant increase ( P  , .0002, paired  t test) in pH from 
7.28   0.08 to 7.34   0.07. The effects of the applica-
tion of ECCO 2 R in group 1 patients (n  5 6) are shown 
in  Figure 3 , indicating continuing decrease in Pa co 2 
and increase in pH with time. Arterial P o 2 was main-
tained within acceptable values with appropriate 
adjustment of the F io 2 . In group 3 patients, who were 
on invasive mechanical ventilation, precise changes 
in Pa co 2 and pH speciﬁ cally due to the application of 
ECCO 2 R cannot be accurately assessed because of 
ventilator setting adjustments; nevertheless, the data 
on CO 2 removal rates ( Fig 2 ) indicate that the Pa co 2 
would very likely have decreased with constant venti-
lator settings. 
 There was no evidence of clinically signiﬁ cant hemo-
lysis in any of the patients; liver and renal function 
were not adversely affected by the ECCO 2 R (e-Table 2). 
Plasma-free hemoglobin, an index of hemolysis, 
increased above 40 mg/100 mL in only two patients, 
in both of whom the increase was attributable to con-
comitant clinical events. Self-limited thrombocytopenia, 
most likely related to heparin use, was noted in eight 
patients. In only two patients did the platelet count 
drop transiently below 85,000/ m L; none of the patients 
required platelet transfusion. A signiﬁ cant thrombo-
cytopenia was seen posttherapy in one patient who 
received 3 units of plasma. Adverse events attributable 
to catheter placement consisted of one death secondary 
to blood loss from perforation of the left iliac vein 
( Table 1 : group 3, subject 4), and one pneumothorax 
which resolved with treatment. In one subject a deep 
venous thrombosis was noted in the cannulated vein 
3 days after the catheter had been removed, causing 
no further adverse effects. 
 Signiﬁ cant bleeding events requiring blood trans-
fusion occurred in three patients: In two cases the 
bleeding was related to underlying disease and antico-
agulation, and in one subject it was due to inadvertent 
due to their underlying disease states. Both patients 
in group 2 were weaned off continuous NIPPV with 
the application of ECCO 2 R, but remained on inter-
mittent NIPPV support, and were alive 30 days after 
completion of therapy. 
 In group 3, nine of 11 patients had been on invasive 
mechanical ventilation for  . 15 days prior to ECCO 2 R. 
Three patients were weaned off invasive mechanical 
ventilation, and in three further patients, the level of 
invasive ventilatory support was reduced. Only one 
patient remained on the same level of ventilatory 
sup port. One patient in group 3 died as a result of a 
retroperitoneal bleed following catheterization and 
received ECCO 2 R support for  , 3 h. At follow-up, 
after the cessation of ECCO 2 R therapy, seven patients 
died ( Table 1 ). One patient in group 1 (patient 4, 
 Table 1 ) suffered a cardiopulmonary arrest within 
24 h of ECCO 2 R cessation, and the other patients 
died of vary ing causes between 7 and 26 days after 
completion of ECCO 2 R. None of these deaths could 
be attributed to the ECCO 2 R, and this mortality rate 
of 35% is not unexpected, given the severity of COPD 
and respiratory failure in these patients. 6,9,10 This mor-
tality rate compares with in-hospital mortality rates 
of 29.3%, 6,10  and 1-year mortality of 49.1% to 62% 9,10  
in similar patients. 
 Figure 1. The Hemolung15.5F double-lumen extracorporeal 
CO 2 removal (ECCO 2 R) catheter with an optional femoral or jug-
ular conﬁ guration. 
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CO 2 in hypercapnic patients with COPD, with side 
effects primarily related to and similar to those seen 
with central venous catheter placement used with extra-
corporeal therapies. 17 The device was consistently 
able to remove  . 80 mL/min of CO 2 over several days 
of continuous use at blood ﬂ ow ranging between 300 
and 550 mL/min through the extracorporeal circuit. 
 The overall mortality rate was very similar to that 
reported in comparable patients not receiving 
ECCO 2 R, 6,9,10 and it could be argued that the absence 
of any signiﬁ cant improvement in mortality makes 
the value of this ECCO 2 R device questionable. How-
ever, this preliminary study was not planned to assess 
excessive anticoagulation. In the two subjects with 
bleeding caused by their underlying disease, one 
(group 3, subject 3,  Table 1 ) was attributed to a new 
diagnosis of von Willebrand disease, and the other 
(group 1, subject 3,  Table 1 ) to an intestinal ulcer. In 
the patient who received excessive anticoagulation 
(group 1, subject 5,  Table 1 ), bleeding occurred from the 
catheter insertion site and a preexisting thoracic drain. 
 Discussion 
 This pilot study supports the feasibility of using this 
single venous catheter ECCO 2 R device for removing 
 Table 2— Ventilatory Parameters 
Subject
Group 1 Group 2 Group 3
1 2 3 4 5 6 7 1 2 1 2 3 4 5 6 7 8 9 10 11
Minute ventilation, L/min
 Baseline, pre-ECCO 2 R 2.5 2.5 6.5 … 7.1 … … … … 7.4 7.0 6.9 4.7 8.6 4.5 11.0 8.4 8.3 7.8 5.9
 Time after ECCO 2 R 
  application
  1 h 2.0 3.4 4.0 15.0 6.0 … … 6.8 9.7 8.0 6.9 3.7 3.5 … 6.8 10.1 7.7 7.1 6.8 9.7
  2 h 4.0 3.5 8.0 16.0 8.0 … … 7.3 10 6.6 7.3 3.5 3.41 … 3.8 6.8 5.5 … 7.3 10.2
 Final 6.8 … 4.9 8.3 8.7 … … 10.4 … 11.7 7.4 8.2 … 8.5 3.4 8.7 8.3 7.6 10.4 …
Frequency, min
 Baseline, pre-ECCO 2 R 18 20 18 22 16 18 … 25 15 15 16 19 15 16 16 20 23 22 25 15
 Time after ECCO 2 R 
  application
  1 h 21 24 13 22 16 … 26 15 15 16 12 12 29 20 33 38 26 26 15
  2 h 18 19 13 22 … … … 26 15 15 16 … 11 30 14 20 23 30 26 15
 Final 23 24 20 22 … … … 26 16 24 11 16 … 11 20 20 24 25 26 16
F io 2 , %
 Baseline, pre-ECCO 2 R … … 30 44 28 30 44 40 35 35 35 45 35 30 30 40 50 32 36 30
 Time after ECCO 2 R 
  application
  1 h … … 30 44 … … … 50 35 36 35 50 35 30 30 50 50 40 … 30
  2 h … … 30 44 32 … 28 … 35 36 35 50 35 30 30 50 50 … … 30
 Final … … 30 80 28 … 40 40 35 45 40 75 35 35 30 30 40 40 44 30
IPAP, cm H 2 O                     
 Baseline pre-ECCO 2 R … … 28 30 20 20 … 15 32 … … … … … … … … … … …
 Time after ECCO 2 R 
  application 
  1 h … … … … 20 … … … 32 … … … … … … … … … … …
  2 h … … 12 … 20 … … 24 32 … … … … … … … … … … …
 Final … … 30 32 20 … … 24 30 … … … … … … … … … … …
EPAP, cm H 2 O
 Baseline, pre-ECCO 2 R … … 12 4 6 8 … 5 10 … … … … … … … … … … …
 Time after ECCO 2 R 
  application 
  1 h … … … … 6 … … … 10 … … … … … … … … … … …
  2 h … … 12 … 6 … … 5 10 … … … … … … … … … … …
 Final … … 10 6 5 … … 5 8 … … … … … … … … … … …
PEEP, cm H 2 O                     
 Baseline, pre-ECCO 2 R … … … … … … … … … 4 5 9 10 15 8 7 8 5 6 5
 Time after ECCO 2 R 
  application 
  1 h … … … … … … … … … 4 5 … 10 15 8 10 8 5 6 5
  2 h … … … … … … … … … 4 6 8 9 15 10 10 8 5 6 5
 Final … … … … … … … … … 4 8 10 … 7 8 10 6 5 6 5
EPAP  5 expiratory positive airway pressure; IPAP  5 inspiratory positive airway pressure; PEEP  5 positive end-expiratory pressure. See Table 1 for 
expansion of other abbreviations.
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application was associated with a decrease in the level 
of perceived dyspnea. 
 The single death directly attributable to the catheter 
placement was, as noted previously, due to internal 
hemorrhage from vessel perforation. This is a well-
known adverse event with central venous catheter 
placement and is not unique to this device. 17 A more 
common side effect, thrombocytopenia, was likely 
related to heparin use. However, in the majority of 
cases, this was not associated with clinically signiﬁ cant 
bleeding. The current system is not an oxygenation 
device; in animal studies, the maximum oxygen uptake 
that can be achieved with the device at blood ﬂ ow 
rates of 400 to 500 mL/min is 25 to 35 mL/min. 
 ECCO 2 R has been used as an adjunct to prevent 
lung damage in patients with ARDS. 12 The original 
technique required a pump-driven venovenous bypass, 
utilizing large catheters (21–28F size) and relatively 
high blood ﬂ ows (25%–30% of cardiac output), with a 
high incidence of side effects. 18,19 These factors, as well 
as the negative results of a clinical trial, 20 prevented 
widespread clinical application of this technique. 
 Further innovations have led to the development 
of two different CO 2 removal techniques: a pumpless 
arteriovenous system, the interventional lung assist 
device (Novalung GmbH), and a pump-driven low 
improvements in mortality outcomes, and the data are 
insufﬁ cient to provide deﬁ nitive conclusions in this 
regard. On the other hand, mortality is signiﬁ cantly 
better in patients treated with NIPPV who avoid intu-
bation and IPPV, 6 and it is possible that ECCO 2 R will 
have a beneﬁ cial effect on mortality; however, a deﬁ n-
itive answer must await a larger, controlled, prospec-
tive study. 
 The most valid data for assessing the effect of the 
device are those seen in patients in group 1. In these 
patients who were on NIPPV, the device was capable 
of reducing the Pa co 2 and increasing pH ( Fig 3 ), and 
none required invasive ventilation. We recognize that 
the decision to proceed to invasive ventilation is depen-
dent on a number of factors and varies with the indi-
vidual treating physician. Nevertheless, given the 
inclusion parameters for this group, the likelihood of 
these patients requiring invasive ventilation is predicted 
to be  . 52%. 14 In group 3, it could be argued that the 
precise effects of the device could be confounded 
by the degree of mechanical ventilatory support and 
adjustments made by the investigator. However, in 
each case, the patients had been on standard treat-
ment and the application of ECCO 2 R resulted in cli-
nical improvement. The data indicate that the device 
 Figure 2. Blood ﬂ ow (mean   SEM) and CO 2 removal (mean   
SEM) through the catheter over time, where n  5 number of sub-
jects at various time points. 
 Figure 3. Changes in Pa co 2 (mean   SEM) and pH (mean   SEM) 
with ECCO 2 R in patients in group 1 (acute exacerbation of COPD 
on noninvasive positive pressure ventilation [NIPPV]). n  5 number 
of subjects; 0 h on abscissa represents baseline values. See Figure 1 
legend for expansion of other abbreviations. 
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blood ﬂ ow venovenous system (Hemodec s.r.l.). The 
pumpless device has been used primarily in patients 
with ARDS as an adjunct to mechanical ventilation. 21 
Both an arterial and a venous catheter are required 
with high blood ﬂ ows of 1.0 to 2.5L/min, ie, 25% to 
50% of cardiac output, and concomitant use of nor-
epinephrine to maintain the pressure gradient. Nev-
ertheless, it is effective in CO 2 removal. Unfortunately, 
serious complications in 12% to 25% of patients, 
including limb ischemia, compartment syndrome, and 
amputation have been reported. 22 The pump-driven 
system uses a smaller catheter and lower blood ﬂ ows 
(up to 400 mL/min). CO 2 exchange is increased by the 
use of a hemodialyzer in the circuit. 23 The actual CO 2 
removal rates have not been stated in these studies. 
 The present pilot study establishes the feasibility of 
using this single venous catheter ECCO 2 R device for 
effective removal of CO 2 at relatively low blood ﬂ ow 
rates in hypercapnic patients. It may be useful in 
the treatment of hypercapnic respiratory failure in 
patients with COPD and, possibly, may have a role in 
assisting protective ventilation in patients requiring 
extreme ventilatory support, such as in severe ARDS. 
A larger, prospective study may help to establish the 
efﬁ cacy and safety of the device and its role in the 
management of respiratory failure. 
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